Novartis’ newest Head for the Grand-Duchy of Luxembourg provides a fascinating insight into the Luxembourg market and reveals how this small nation has found itself in pole position for future pharmaceutical innovation.
After over a decade with GSK, you joined Novartis one and half years ago. What made you join Novartis and what objectives have you been given in developing this affiliate further?
"Our ambition is to strengthen our footprint in Luxembourg and further build meaningful and trustworthy relationships to become the partner of choice for the Luxembourg Health stakeholders."
